1349 On Other Exchanges
Symbol
Exchange
1349 is not on other exchanges.

shanghai fudan-zhangjiang-h (1349) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SHANGHAI FUDAN-ZHANGJIANG-H (1349)

Related News

No related news articles were found.

shanghai fudan-zhangjiang-h (1349) Related Businessweek News

No Related Businessweek News Found

shanghai fudan-zhangjiang-h (1349) Details

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering drugs, including recombinant tissue type plasminogen activator for heart infarction; recombinant human lymphotoxin a-derivatives and Vincristine sulphate liposome that have completed Phase II clinical trials for tumors; recombinant human tumor necrosis recipient Fc fusion protein and rhTNFR(m):Fc for arthritis; PTH that has completed Phase I clinical trials for osteoporosis; CD30-MMAE and Nanoparticle Albumin-bound Paclitaxel that are in pre-clinical study for tumors; and Avastin that has completed pre-clinical study for tumors. The company also provides anti-sclerostin mab that is in pre-clinical study for osteoporosis; and PCSK9 that is in pre-clinical study for hypercholesterolemia. In addition, it offers photodynamic therapy drugs, such as Hemoporfin for port wine stain; Deuteroporphyrin that is in Phase II clinical trials for tumors; Aminolevulinic acid, which is in Phase II clinical trial for cervical diseases infected by HPV; and Aminolevulinic acid that has submitted application for clinical trials for acne, as well as is in pre-clinical study for brain gliomas and basal cell carcinoma. Further, the company provides liposomal drugs comprising Libod, a liposome doxorubicin injection for tumors; and Xenon liposome that is in pre-clinical study for strokes. Additionally, it offers Antenatal screening diagnostic reagent for Down’s syndrome; and food safety inspection reagents for antibiotics inspection. The company also researches and develops biological and medical technology, pharmaceutical projects, and medical diagnostic products, as well as offers technical and general merchandise, and healthcare services. It has strategic agreement with Shanghai Pharmaceuticals Holding Co., Ltd. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.

552 Employees
Last Reported Date: 03/29/16
Founded in 1996

shanghai fudan-zhangjiang-h (1349) Top Compensated Officers

Co-Founder, Executive Chairman, General Manag...
Total Annual Compensation: CNY2.0M
Co-Founder, Deputy General Manager and Execut...
Total Annual Compensation: CNY1.3M
Deputy General Manager and Executive Director
Total Annual Compensation: CNY1.3M
Compensation as of Fiscal Year 2015.

shanghai fudan-zhangjiang-h (1349) Key Developments

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd., Special/Extraordinary Shareholders Meeting, May 13, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd., Special/Extraordinary Shareholders Meeting, May 13, 2016, at 11:00 China Standard Time. Location: No. 308 Cailun Road Zhangjiang Hi-tech Park, Pudong New Area Shanghai Shanghai Province China Agenda: To consider and approve the extension of the validity period of the resolution in respect of the proposed issue of not more than 27,000,000 A shares with a nominal value of RMB 0.10 each; to consider and approve the extension of the authorization period to the board to deal with matters relating to the issue of A Shares.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2015

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. announced audited consolidated earnings results for the year ended December 31, 2015. For the year, the company reported revenue of RMB 579,463,000 against RMB 470,900,000 a year ago. Operating profit was RMB 153,056,000 against RMB 129,960,000 a year ago. Profit before income tax was RMB 145,950,000 against RMB 128,099,000 a year ago. Profit attributable to the shareholders of the company was RMB 127,723,000 against RMB 118,258,000 a year ago. Basic and diluted earnings per share for profit attributable to the shareholders of the company were RMB 0.1384 against RMB 0.1281 a year ago. Net cash generated from operating activities was RMB 96,296,000 against RMB 88,359,000 a year ago. Purchase of property, plant and equipment was RMB 38,250,000 against RMB 44,089,000 a year ago. Purchase of intangible assets was RMB 1,498,000 against RMB 816,000 a year ago. EBITDA was RMB 182,070,000 against RMB 155,748,000 a year ago. The total revenue for the year 2015 mainly came from the sale of medical products, revenue recognised from exclusive distribution rights and the revenue from technology transfer. The source of total revenue for the year 2015 was the same as that for the year of 2014.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Proposes Final Dividend for the Year Ended of December 31, 2015, Payable on July 08, 2016

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. proposed to distribute a final dividend of RMB 0.03 per share (tax inclusive) for the year ended December 31, 2015. If the profit distribution plan is approved by the shareholders by way of an ordinary resolution at the 2015 annual general meeting to be held on May 13, 2016, the final dividend is expected to be distributed on July 08, 2016 to all shareholders whose names appear on the register of the company on May 26, 2016.

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

1349 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1349.
View Industry Companies
 

Industry Analysis

1349

Industry Average

Valuation 1349 Industry Range
Price/Earnings 42.9x
Price/Sales 9.5x
Price/Book 7.5x
Price/Cash Flow 42.9x
TEV/Sales 8.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SHANGHAI FUDAN-ZHANGJIANG-H, please visit www.fd-zj.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.